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EDITORIAL
Compound interest: ACE and PAI-1 polymorphisms and risk of
thrombosis and fibrosis
Plasminogen activator inhibitor-1 (PAI-1) is the major
inhibitor of tissue-type plasminogen activator (t-PA) and
urokinase-type plasminogen activator (u-PA), and plays a
critical role in regulating intravascular fibrinolysis. The
nascent appreciation for the role of plasmin as a regulator
of tissue repair and remodeling, both directly and indirectly
via its role in activating matrix metalloproteases (MMPs),
has also brought attention to PAI-1 as a factor that may
contribute to the development of fibrosis in tissues. The
renin-angiotensin-aldosterone system (RAAS) has broad
impact on progression of sclerotic vascular diseases, both
via hemodynamic and nonhemodynamic mechanisms, the
latter including cell growth and matrix elaboration. We and
others have shown that angiotensin directly induces PAI-1
expression in vitro in cells relevant to vascular sclerosis,
including endothelial, vascular smooth muscle and mesan-
gial cells. Conversely, inhibition of the RAAS with angio-
tensin converting enzyme (ACE) inhibitors has been shown
to reduce the rate of deterioration of renal function even in
nonhypertensive patients with progressive renal diseases.
Physiological interactions between the RAAS and the
fibrinolytic system have previously been demonstrated.
Activation of the RAAS has been linked to increased
plasma PAI-1 levels. Relatively short-term infusions of
angiotensin II in normotensive subjects resulted in in-
creased plasma PAI-1 concentrations without any corre-
sponding changes in t-PA antigen levels [1]. Conversely,
ACE inhibition in patients after acute myocardial infarc-
tion resulted in decreased PAI-1 levels and activities [2].
This tight link between angiotensin and PAI-1 was also
demonstrated in animal studies with aortic injury [3] or
renal microvascular injury induced by radiation [4]. Injury
in the radiation model is initially manifest by glomerular
thrombosis followed by sclerosis, and was prevented by
pharmacological inhibition of the RAAS using either an
angiotensin type 1 receptor blocker or an ACE inhibitor,
which decreased, but did not normalize, the increased
PAI-1 expression. In the rat, the induction of PAI-1
expression by angiotensin in various organs appears to be
mediated by the type 1 angiotensin receptor, and is not
dependent on angiotensin’s hemodynamic effects [5]. In
contrast, in endothelial cells in vitro, the type 4 angiotensin
receptor appears to mediate angiotensin-induced PAI-1
expression [6]. The specific mechanisms that regulate the
interaction of the RAAS and PAI-1 in humans have not
been definitively determined. This could have important
implications for strategies to optimally inhibit both RAAS
and PAI-1-mediated adverse events in human disease.
Common functional genetic polymorphisms have been
shown to modulate activities of these systems. ACE activity
is increased in normal individuals with the deletion (D)
allele of ACE compared to the insertion (I) allele. Patients
with D allele have augmented risk for cardiovascular
disease [7] and progression in both diabetic and non-
diabetic renal diseases in some, but not all, studies. There
is also genetic modulation of PAI-1 activity by the common
4G/5G polymorphism located 2675 basepairs from the
transcription start of PAI-1. Patients homozygous for the
4G allele have increased PAI-1 levels, and also increased
risk for cardiovascular disease [8].
Several studies have shown a link between the ACE D
allele and PAI-1 levels in Asians, Caucasians and African
Americans. The studies by Kimura et al in this issue of
Kidney International [9] suggest that compound homozygos-
ity (that is, D/D 1 4G/4G) in these polymorphisms of
RAAS and PAI-1, is an important contributor to macroan-
giopathic disease (ischemic heart disease, myocardial in-
farct, cerebrovascular disease or peripheral vascular dis-
ease).
Somewhat surprisingly, there was no association between
the ACE D/D genotype and progression of diabetic ne-
phropathy. However, classification of patients as having
diabetic nephropathy was based on clinical, not pathologic,
criteria. Although retinopathy is tightly linked with pres-
ence of diabetic nephropathy in type 1 diabetes, this is not
the case in type 2 diabetes. Further, serum creatinine is a
poor indicator of renal function, especially in diabetics
where hyperfiltration and renal growth actually decrease
serum creatinine in the absence of sclerosis. Thus, increase
of serum creatinine to “normal” levels in the diabetic likely
indicates substantial sclerosis is already present. As many as
two-thirds of type 2 diabetics with proteinuria are likely to
have non-diabetic disease, including nonspecific hyperten-
sive changes and various other glomerular diseases, some
of which may be relatively less influenced by angiotensin-
related mechanisms. Thus, in view of these limitations, the
lack of an effect of ACE D or PAI-1 4G on renal disease
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progression in this study cannot be taken as definitive
evidence, given previous studies in populations with pre-
cisely defined renal disease where D/D genotype was
associated with worse prognosis [10]. It is also, however,
possible that the effects of interactions between the RAAS
and PAI-1 are particularly important, and therefore detect-
able in this small sample, in macrovascular diseases where
both thrombotic and fibrotic mechanisms impact on tissue
injury. Thrombosis is not part of the classic spectrum of
morphologic lesions in diabetic nephropathy, and the ex-
tent of impact of interactions of thrombotic and sclerotic
mechanisms may be of lesser magnitude for diabetic ne-
phropathy versus myocardial infarct, cerebrovascular dis-
ease or peripheral vascular disease where thrombosis typ-
ically precedes end organ damage.
The current study points to the adverse consequences
when thrombotic or fibrotic mechanisms are activated, and
the ominous prognosis when functionally high risk alleles
implicated in both pathways are present. The study also
points to potential therapeutic targets presented by inhibi-
tion of the renin-angiotensin system and its partner in
injury, PAI-1. Recent data also suggests that aldosterone
levels correlate well with plasma PAI-1 antigen [11]. Thus,
the increased aldosterone levels seen in the setting of an
activated RAAS may also contribute to increased PAI-1
production. The link between gene polymorphisms of the
RAAS and PAI-1 and vascular disease shown in the studies
by Kimura et al also provides an additional mechanism
whereby ACEI or other inhibitors of the RAAS might exert
benefit on sclerotic mechanisms, namely by decreasing
PAI-1 activity and the consequent activation of both throm-
botic and sclerotic injuries. However, further studies are
needed to define the biological interactions between the
RAAS and the fibrinolytic system, and the impact of
common genetic polymorphisms in ACE and PAI-1 on the
progression of cardiovascular and renal diseases.
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